Pre-made Stamulumab benchmark antibody (Whole mAb, anti-MSTN/GDF-8 therapeutic antibody, Anti-GDF8/MSLHP Antibody) for drug discovery and mechanism of action (MOA) research

Anti-MSTN/GDF-8 therapeutic antibody (Pre-made Stamulumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Stamulumab (MYO-29[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania.[2] Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-999-1mg	1mg	3090
GMP-Bios-INN-999-10mg	10mg	Inquiry
GMP-Bios-INN-999-100mg	100mg	Inquiry
GMP-Bios-INN-999-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Stamulumab Biosimilar, Whole Mab, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody
INN Name	Stamulumab
Target	MSTN/GDF-8
Format	Whole mAb
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG1 - nd
VD LC	IgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Wyeth Pharmaceuticals (Madison NJ USA) / Cambridge Antibody Technology (Cambridge UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0